IBI-Ag News
7 articles
growth-positive
The company’s single-domain antibody technology aims to redefine sustainable agriculture.
IBI Ag, a company specializing in bio-insecticides with a lower ecological footprint, has secured $6.1 million in the first part of its Series A funding round. The investment was led by Corteva, Inc., with participation from The Trendlines Group, Iron Nation, Consensus Business Group, and a grant from the Israel Innovation Authority. IBI Ag is developing technology using single-domain antibodies to create effective crop protection solutions that minimize environmental impact. The funding will accelerate the development of this technology, initially targeting high-value crops with plans to expand into row crops.
Investment
growth-positive
/PRNewswire/ -- IBI Ag, a pioneering crop protection company developing a wide array of bio-insecticides with a lower ecological footprint, today announced it...
IBI Ag, a company focused on developing sustainable bioinsecticides, has successfully closed the first tranche of its Series A funding round, raising $6.1 million. The investment was led by Corteva through its Corteva Catalyst platform, with participation from The Trendlines Group, Iron Nation, Consensus Business Group, and a grant from the Israel Innovation Authority. IBI Ags technology uses single domain antibodies to create effective crop protection solutions with minimal ecological impact. The funding will accelerate the development of this technology, which targets a broad spectrum of insects and aims to provide environmentally friendly alternatives to chemical pesticides.
Investment
growth-positive
Exclusive: IBI Ag clinches $6.1m round led by Corteva to scale up 'cost-effective' bioinsecticides
IBI Ag, an Israel-based bioinsecticide company, has raised $6.1 million in the first tranche of its Series A funding round. The round was led by Corteva through its investment and partnership platform, Corteva Catalyst, and included participation from the Trendlines Group, Iron Nation, Consensus Business Group, and the Israel Innovation Authority. IBI Ag specializes in developing cost-effective nanobodies for agricultural use, which are smaller and more efficient than traditional antibodies. The company is currently conducting field trials and plans to start the regulatory process in the US by the end of the year. The funding will be used to scale up production and regulatory efforts, with plans to expand into Latin America and Europe.
InvestmentPartnersProduct Stage
growth-positive
IBI Ag, a Nes Tziona, Israel-based crop protection company, raised $6.1M in funding
IBI Ag, an Israel-based crop protection company, has raised $6.1 million in funding. The investment round was led by Corteva and included participation from The Trendlines Group, Iron Nation, Consensus Business Group, and a grant from the Israel Innovation Authority. The funds will be used to strengthen the companys position in the global agricultural sector by developing innovative crop protection solutions. IBI Ags technology uses single domain antibodies to create effective and environmentally friendly crop protection products, targeting a wide range of insects while minimizing impact on non-target organisms.
Investment
growth-positive
החברה שרוצה להדביר את חומרי ההדברה
Israeli ag-tech company IBIAg is developing a new generation of bio-insecticides that are safe for the environment and can be used immediately before consumption. The companys products are based on a tiny antigen that, when modified using biotechnology, can kill pests. IBIAg, which has received around $6 million in investment to date, is currently in the lab testing phase and expects to have its first product ready within two years.
Investment
growth-positive
IBI-Ag Completes Funding Round for its New Class of Bioinsecticides
IBI-Ag, a biotechnology company, has announced an investment round to optimize its first product and expand its product portfolio spectrum. The round includes investments from the Bayer-Trendlines Ag Innovation Fund, Agriline, and The Trendlines Group. IBI-Ag is developing natural, single domain antibody insecticides to increase crop production without harm to farmers, consumers, and the environment. The company aims to provide novel and effective nature-driven solutions to the insect pest problem in agriculture. The investment round is seen as a vote of confidence in IBI-Ags progress and its commitment to environmental sustainability.
Investment
Bayer Trendlines Ag Innovation Fund makes first investment - The Trendlines Group
